

## Product datasheet for TR309675

## RYBP Human shRNA Plasmid Kit (Locus ID 23429)

## **Product data:**

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Product Type:	shRNA Plasmids
Product Name:	RYBP Human shRNA Plasmid Kit (Locus ID 23429)
Locus ID:	23429
Synonyms:	AAP1; APAP-1; DEDAF; YEAF1
Vector:	pRS (TR20003)
E. coli Selection:	Ampicillin
Mammalian Cell Selection:	Puromycin
Format:	Retroviral plasmids
Components:	RYBP - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 23429). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
RefSeq:	<u>NM 012234</u> , <u>NM 012234.1, NM 012234.2</u> , <u>NM 012234.3</u> , <u>NM 012234.4</u> , <u>NM 012234.5</u> , <u>BC036459, BC036459.1, BC014959</u>
UniProt ID:	<u>Q8N488</u>



This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2023 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US

ORIGENE	RYBP Human shRNA Plasmid Kit (Locus ID 23429) – TR309675	

Summary:	Component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development. PcG PRC1-like complex acts via chromatin remodeling and modification of histones; it mediates monoubiquitination of histone H2A 'Lys-119', rendering chromatin heritably changed in its expressibility (PubMed:25519132). Component of a PRC1-like complex that mediates monoubiquitination of histone H2A 'Lys-119' on the X chromosome and is required for normal silencing of one copy of the X chromosome in XX females. May stimulate ubiquitination of histone H2A 'Lys-119' by recruiting the complex to target sites (By similarity). Inhibits ubiquitination and subsequent degradation of TP53, and thereby plays a role in regulating transcription of TP53 target genes (PubMed:19098711). May also regulate the ubiquitin-mediated proteasomal degradation of other proteins like FANK1 to regulate apoptosis (PubMed:14765135, PubMed:27060496). May be implicated in the regulation of the transcription as a repressor of the transcriptional activity of E4TF1 (PubMed:11953439). May bind to DNA (By similarity). May play a role in the repression of tumor growth and metastasis in breast cancer by down-regulating SRRM3 (PubMed:27748911).[UniProtKB/Swiss-Prot Function]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u> . If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u> .
<b>P</b> (	

PerformanceOriGene guarantees that the sequences in the shRNA expression cassettes are verified toGuaranteed:correspond to the target gene with 100% identity. One of the four constructs at minimum are<br/>guaranteed to produce 70% or more gene expression knock-down provided a minimum<br/>transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to<br/>evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly<br/>assess knockdown, the gene expression level from the included scramble control vector must<br/>be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2023 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US